Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C

Journal of Gastrointestinal and Liver Diseases

Volumn 21, Issue 4, 2012, Pages 367-373

  Forestier, Nicole ^a   Gaus, Antonia ^a   Herrmann, Eva ^b   Sarrazin, Christoph ^a   Bojunga, Joerg ^a   Poynard, Thierry ^c   Albert, Joerg ^a   Gerber, Ludmila ^a   Schneider, Maximilian David ^a   Dultz, Georg ^a   Zeuzem, Stefan ^a   Friedrich Rust, Mireen ^a  

^a Department of Internal Medicine 1 ^*  (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ARFI; Elastography; Liver stiffness; Non response; Relapse; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PEGINTERFERON; RIBAVIRIN;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ADULT; AGED; ARTICLE; DRUG RESPONSE; ELASTOGRAPHY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RIGIDITY; SCORING SYSTEM; THROMBOCYTE COUNT; TREATMENT RESPONSE; ULTRASOUND;

ADULT; AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84875068576     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
2. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-342.
3. Poynard T, Munteanu M, Colombo M, et al. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(3) program. J Hepatol 2011; 54:227-235.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
6. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
8. Kluwe J, Pradere JP, Gwak GY, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138:347-359.
9. Patsenker E, Schneider V, Ledermann M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55:388-398.
10. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500.
11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
12. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-974.
13. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5:1214-1220.
14. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44:214-219.
15. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102:2589-2600.
16. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:557-576.
17. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both signifcant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
19. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19:e212-e219.
20. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38:481-492.
21. Vergniol J, Foucher J, Castera L, et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16:132-140.
22. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83:127-134.
23. Palmeri ML, Wang MH, Dahl JJ, Frinkley KD, Nightingale KR. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34:546-558.
24. Nightingale K, McAleavey S, Trahey G. Shear-wave generation using acoustic radiation force: in vivo and ex vivo results. Ultrasound Med Biol 2003; 29:1715-1723.
25. Sarvazyan AP, Rudenko O V, Swanson SD, Fowlkes JB, Emelianov SY. Shear wave elasticity imaging: a new ultrasonic technology of medical diagnostics. Ultrasound Med Biol 1998; 24:1419-1435.
26. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-1713.
27. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56:968-973.
28. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (Fibroscan): a prospective study. Gut 2006; 55:403-408.
29. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
30. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical vaiability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42:323-333.
31. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-1355.
32. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
33. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52:1887-1896.
34. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59:1245-1251.
35. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140:1970-1979.
36. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-431.